Leerink Partners initiated coverage on shares of Erasca (NASDAQ:ERAS – Free Report) in a report released on Tuesday morning, MarketBeat Ratings reports. The firm issued an outperform rating and a $35.00 price objective on the stock.
ERAS has been the topic of several other reports. Guggenheim lifted their price target on Erasca from $20.00 to $21.00 and gave the company a “buy” rating in a research report on Thursday, August 13th. HC Wainwright upped their price objective on Erasca from $18.00 to $22.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Erasca in a research note on Tuesday, September 8th. Bank of America raised their target price on Erasca from $18.00 to $20.00 and gave the company a “neutral” rating in a research note on Friday, August 14th. Finally, Morgan Stanley lifted their target price on Erasca from $12.00 to $21.00 and gave the stock an “equal weight” rating in a report on Monday, July 20th. Nine research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $23.17.
Read Our Latest Research Report on ERAS
Erasca Price Performance
Shares of NASDAQ:ERAS opened at $14.22 on Tuesday. Erasca has a 12 month low of $2.75 and a 12 month high of $24.28. The stock has a market cap of $4.99 billion, a price-to-earnings ratio of -14.36 and a beta of 0.68. The stock’s 50 day moving average price is $14.81 and its 200 day moving average price is $15.33.
Erasca (NASDAQ:ERAS – Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). On average, sell-side analysts expect that Erasca will post -0.51 EPS for the current year.
Institutional Trading of Erasca
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new stake in shares of Erasca during the 2nd quarter valued at $387,544,000. ARCH Venture Management LLC bought a new stake in shares of Erasca during the 2nd quarter worth $129,917,324. Janus Henderson Group PLC acquired a new position in shares of Erasca in the 1st quarter worth $59,988,000. Assenagon Asset Management S.A. grew its holdings in shares of Erasca by 407.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 4,128,332 shares of the company’s stock worth $60,521,000 after acquiring an additional 3,315,456 shares during the last quarter. Finally, Commodore Capital LP acquired a new position in shares of Erasca in the 1st quarter worth $51,372,000. 67.78% of the stock is owned by institutional investors and hedge funds.
More Erasca News
Investors following ERAS have been watching these news items:
- Positive Sentiment: Erasca and BMS will evaluate ERAS-0015 with navlimetostat in a clinical study for pancreatic cancer. The partnership brings a major pharmaceutical company into testing the combination and may strengthen investor confidence in the program; clinical results are still needed to establish its potential. Erasca and BMS clinical collaboration
- Positive Sentiment: Recent coverage has spotlighted ERAS-0015, with a Phase 1 update anticipated and reports describing strong interest in the drug. An update could provide investors with important early evidence about the treatment, although no clinical outcome is established by these reports. STAT coverage of Erasca’s KRAS-targeted treatment Seeking Alpha analysis of ERAS-0015
- Positive Sentiment: Analyst attention has also increased: Leerink Partners initiated coverage, and a separate report said estimated fair value edged higher amid optimism about ERAS-0015. The headlines do not specify Leerink’s rating or target, so the impact of its coverage is unclear. Leerink Partners coverage initiation Erasca fair-value report
Erasca Company Profile
Erasca, Inc. is a clinical-stage biotechnology company focused on developing medicines for cancer. Its research centers on the RAS/MAPK signaling pathway, which is involved in the growth of many tumors and can be difficult to target with existing therapies. The company’s pipeline includes investigational drug candidates designed to inhibit RAS proteins and other targets in the pathway. Erasca evaluates these candidates for potential use across multiple cancer types; its medicines remain in development rather than being marketed as approved treatments.
Recommended Stories
- Five stocks we like better than Erasca
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Erasca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erasca and related companies with MarketBeat.com's FREE daily email newsletter.
